JP2021513564A5 - - Google Patents

Info

Publication number
JP2021513564A5
JP2021513564A5 JP2020564818A JP2020564818A JP2021513564A5 JP 2021513564 A5 JP2021513564 A5 JP 2021513564A5 JP 2020564818 A JP2020564818 A JP 2020564818A JP 2020564818 A JP2020564818 A JP 2020564818A JP 2021513564 A5 JP2021513564 A5 JP 2021513564A5
Authority
JP
Japan
Prior art keywords
approximately
biphenyl
degrees
mixture
trimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513564A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017833 external-priority patent/WO2019160940A1/en
Publication of JP2021513564A publication Critical patent/JP2021513564A/ja
Publication of JP2021513564A5 publication Critical patent/JP2021513564A5/ja
Pending legal-status Critical Current

Links

JP2020564818A 2018-02-13 2019-02-13 グルカゴン受容体拮抗薬 Pending JP2021513564A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862630190P 2018-02-13 2018-02-13
US62/630,190 2018-02-13
US201862635461P 2018-02-26 2018-02-26
US62/635,461 2018-02-26
PCT/US2019/017833 WO2019160940A1 (en) 2018-02-13 2019-02-13 Glucagon receptor antagonists

Publications (2)

Publication Number Publication Date
JP2021513564A JP2021513564A (ja) 2021-05-27
JP2021513564A5 true JP2021513564A5 (https=) 2022-02-21

Family

ID=65529861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564818A Pending JP2021513564A (ja) 2018-02-13 2019-02-13 グルカゴン受容体拮抗薬

Country Status (6)

Country Link
US (1) US12208071B2 (https=)
EP (1) EP3752249A1 (https=)
JP (1) JP2021513564A (https=)
CN (1) CN111954560A (https=)
TW (1) TW202003453A (https=)
WO (1) WO2019160940A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524846A (en) 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
JPH0738070B2 (ja) 1986-07-25 1995-04-26 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
DE3860351D1 (de) 1987-03-09 1990-08-30 Eastman Kodak Co Photographische silberhalogenidmaterialien und verfahren, das einen pyrazoloazolkuppler enthaelt.
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5780058A (en) 1995-07-21 1998-07-14 Alza Corporation Oral delivery of discrete units
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
JPH09241284A (ja) 1996-03-08 1997-09-16 Koji Yamashita 新規なオキシアザホスホリン誘導体
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
JPH1197740A (ja) 1997-09-19 1999-04-09 Showa Denko Kk ＧａＰ発光ダイオード用エピタキシャルウェーハおよびＧａＰ発光ダイオード
AU1623099A (en) 1997-12-22 1999-07-12 Alza Corporation Rate controlling membranes for controlled drug delivery devices
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
AU1937099A (en) 1997-12-31 1999-07-19 Alza Corporation Osmotic drug delivery monitoring system and method
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
IL142807A0 (en) 1998-11-02 2002-03-10 Alza Corp Controlled delivery of active agents
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
DE60023492T2 (de) 1999-05-17 2006-07-20 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
CA2374947A1 (en) 1999-05-24 2000-11-30 Robert M. Scarborough Inhibitors of factor xa
ATE329920T1 (de) 1999-09-10 2006-07-15 Novo Nordisk As Modulatoren der protein tyrosin phosphatase (ptpases)
DE10008329A1 (de) 2000-02-23 2001-08-30 Merck Patent Gmbh Aminosulfonylbiphenylderivate
HUP0301501A2 (hu) 2000-06-23 2003-08-28 Novo Nordisk A/S Glükagon antaagonista/inverz agonista vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása gyógyászati készítmények előállítására
AU2002223501A1 (en) 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
JP2005511683A (ja) 2001-12-03 2005-04-28 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
US20030212119A1 (en) 2001-12-20 2003-11-13 Jesper Lau Novel glucagon receptor antagonists/inverse agonists
EP1519723A1 (en) 2002-06-27 2005-04-06 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
CA2508581A1 (en) 2002-12-04 2004-06-17 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
US20040152750A1 (en) 2002-12-20 2004-08-05 Kodra Janos Tibor Novel glucagon antagonists
AU2004210127B2 (en) 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
US7138529B2 (en) 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
CA2524436A1 (en) 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
US20070054902A1 (en) 2003-12-02 2007-03-08 Shionogi & Co., Ltd. Isoxazole derivatives as peroxisome proliferator-activated receptors agonists
US20070015757A1 (en) 2003-12-19 2007-01-18 Novo Nordisk A/S Novel Glucagon Antagonists/Inverse Agonists
CA2547785A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
US7989457B2 (en) 2004-05-28 2011-08-02 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
NZ551405A (en) 2004-06-04 2009-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use
CN1968921B (zh) 2004-06-14 2011-11-23 伊莱利利公司 胰高血糖素受体拮抗剂、制备和治疗用途
CA2584502A1 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
CN1980665A (zh) 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
WO2006014618A2 (en) 2004-07-22 2006-02-09 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
ES2332470T3 (es) 2005-02-11 2010-02-05 Eli Lilly And Company Derivados de tiofeno sustituidos como antagonistas del receptor de glucagon, preparacion y usos terapeuticos.
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
JP2008534593A (ja) 2005-03-30 2008-08-28 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法
CN101300232A (zh) 2005-07-26 2008-11-05 默克公司 合成取代的吡唑的方法
CA2623762A1 (en) 2005-09-19 2007-03-29 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Modulation of glucagon receptor expression
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
WO2007106181A2 (en) 2005-11-17 2007-09-20 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
WO2007114855A2 (en) 2005-11-18 2007-10-11 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
CN101312723B (zh) 2005-11-22 2012-01-11 伊莱利利公司 胰高血糖素受体拮抗剂、制备和治疗用途
ATE459619T1 (de) 2005-11-23 2010-03-15 Lilly Co Eli Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7935713B2 (en) 2006-05-16 2011-05-03 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP5258563B2 (ja) 2006-06-29 2013-08-07 日産化学工業株式会社 αアミノ酸誘導体及びそれを有効成分として含む医薬
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN101595089A (zh) 2006-12-02 2009-12-02 财团法人首尔大学校产学协力财团 作为ppar配体的芳基化合物及其用途
KR20200123866A (ko) 2007-02-09 2020-10-30 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
PT2799428T (pt) 2008-08-13 2017-02-17 Metabasis Therapeutics Inc Antagonistas de glicagina
CN103813794A (zh) 2011-07-18 2014-05-21 拓凯制药公司 用于治疗前列腺癌的新型组合物及方法
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN106336387A (zh) * 2015-07-10 2017-01-18 浙江海正药业股份有限公司 酰胺类衍生物、其制备方法及其在医药上的用途
US20170143673A1 (en) * 2015-11-24 2017-05-25 Remd Biotherapeutics, Inc. Methods For Treating Heart Failure Using Glucagon Receptor Antagonists
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists

Similar Documents

Publication Publication Date Title
US7674935B2 (en) Crystal forms of O-desmethylvenlafaxine
CN1083830C (zh) 经取代的苄脒,其制备及作为药物化合物的用途
CN105198760A (zh) 芬戈莫德的盐
US20040171665A1 (en) Crystalline solids of carvedilol and processes for their preparation
CN1543468A (zh) 制备他汀类的钙盐形式的方法
JP2017105780A (ja) 相乗作用性組成物
CN1561341A (zh) 用氢氧化钙水解[R(R*,R*)]－2－(4－氟代苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[（苯基氨基）羰基]－1H－吡咯－1－庚酸酯
CA3195789A1 (en) Solid state forms of resmetirom
US7994178B2 (en) Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
JP4393376B2 (ja) フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用
JP2011513341A (ja) キノリン類化合物及びその医薬組成物、製造方法並びに使用
SK287644B6 (sk) Kryštalický N-(trans)-4-izopropylcyklohexylkarbonyl)-D- fenylalanín vo forme C a spôsob jeho prípravy
JP2021513564A5 (https=)
US7417165B2 (en) Crystalline forms of pregabalin
WO2022147519A1 (en) Solid state forms of capivasertib and process for preparation thereof
TW201618763A (zh) 用於預防及治療糖尿病之經取代之芳族化合物及醫藥組合物
IL186221A (en) Crystalline rosuvastatin intermediate
WO2024095127A1 (en) Solid state forms of tivozanib and process for preparation thereof
EP4508035A1 (en) Solid state forms of mavacamten and process for preparation thereof
WO2022177927A1 (en) Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
CA3185726A1 (en) Dual regulator for mglur5 and 5-ht2a receptors and use thereof
US12616701B2 (en) Solid state forms of Resmetirom
EP4051659B1 (en) Solid state forms of fezagepras and process for preparation thereof
CN111954560A (zh) 胰高血糖素受体拮抗剂
CN1362948A (zh) 3s－3－氨基－3－芳基丙酸及其衍生物的制备方法